Plain-English translation of NCT03198052 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of immunotherapy called CAR-T cell therapy. Researchers will take some of your own immune cells (T cells), genetically engineer them in the lab to recognize proteins on your cancer cells, and then infuse them back into your body. The goal is to help your immune system fight the cancer more effectively.
Advanced cancers often evade the body's natural immune defenses, and standard treatments don't work for everyone. This trial explores whether teaching your own immune cells to target specific cancer proteins could offer a new treatment option for patients whose cancers express these target proteins.
You likely qualify if…
You likely don't qualify if…
You will first have a biopsy to confirm your cancer has the target proteins. Then doctors will collect blood cells from you, engineer them in the lab over several weeks, and infuse them back into your body through injection. You will receive at least 3 cycles of treatment and have close follow-up visits to monitor how well the treatment works and any side effects you experience.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China